Put companies on watchlist
HBM Healthcare Investments AG
ISIN: CH0012627250
WKN: 984345
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

HBM Healthcare Investments AG · ISIN: CH0012627250 · EQS - adhoc news (191 News)
Country: Switzerland · Primary market: Switzerland · EQS NID: 1201131
27 May 2021 06:30AM

Publication of Annual Report 2020/2021 and Invitation to the Ordinary Shareholders' Meeting


EQS Group-Ad-hoc: HBM Healthcare Investments AG / Key word(s): Annual Results
Publication of Annual Report 2020/2021 and Invitation to the Ordinary Shareholders' Meeting

27-May-2021 / 06:30 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 KR
The issuer is solely responsible for the content of this announcement.


The invitation to the 20th Ordinary Shareholders' Meeting on 18 June 2021 has been sent to the shareholders of HBM Healthcare Investments today.

In accordance with the Ordinance 3 on Measures to Combat the Coronavirus (COVID-19), issued by the Swiss Federal Council, this year's Ordinary Shareholders Meeting is not held in the usual form, i.e. the shareholders are not permitted to participate in person. The Board of Directors has resolved in accordance with Art. 27 of the said Ordinance, that the shareholders may exercise their rights exclusively through the independent proxy by way of written or electronic instruction and power of attorney.
 

The detailed invitation with all motions of the Board of Directors is enclosed and displayed on the Company's website www.hbmhealthcare.com/en/news.

Agenda for the 20th Ordinary Shareholders' Meeting on 18 June 2021

1.    Statutory financial statements and group financial statements 2020/2021; reports of the
       auditors

2.    Discharge from liability of the members of the Board of Directors and Management

3.    Appropriation of results
       - Appropriation of disposable profit of CHF 283'034'893.

4.    Elections regarding the Board of Directors
       - Re-elections of the Chairman and of the Members of the Board of Directors
       - Election of Dr. Eilaine V. Jones as a member of the Board of Directors
       - Election of the Members of the Compensation Committee

5.    Compensation to the Board of Directors and to the Management

6.    Appointment of auditors

7.    Appointment of independent proxy-holder

8.    Reduction of share capital: partial payback of nominal value
       - Cash distribution to shareholders of CHF 12.50 per share through nominal value
          repayment

9.    Miscellaneous

 

HBM Healthcare Investments also published today its Annual Report 2020/2021 on the Company's website www.hbmhealthcare.com/en/investors/financial-reports.

Contact
For further information, please contact Dr Andreas Wicki on +41 41 710 75 77, or at andreas.wicki@hbmhealthcare.com.

About HBM Healthcare Investments

HBM Healthcare Investments invests in the healthcare sector. The Company holds and manages an international portfolio of promising companies in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas. Many of these companies have their lead products already available on the market or at an advanced stage of development. The portfolio companies are closely tracked and actively guided in their strategic direction. This is what makes HBM Healthcare Investments an interesting alternative to investments in big pharma and biotechnology companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

Disclaimer

The publication is for information purposes only and does not constitute an offer to sell or a solicitation to buy or subscribe for securities. This news release does not constitute a prospectus within the meaning of Art. 35ff FinSA, or securities prospectus in the sense of the German securities prospectus law. This news release and the information contained therein is not intended for distribution to the United States of America (USA) or within the USA and may not be distributed or forwarded to US persons (including legal persons) or to publications with a general distribution in the USA. This news release is not an offer or solicitation to buy securities in the United States. HBM Healthcare Investments AG's securities were not issued in accordance with the U.S. U.S. securities laws, and may not be sold, offered for sale, or delivered in the U.S. or to U.S. individuals without prior registration or without a registration exemption. Some information quoted was obtained from external sources HBM considers to be reliable. HBM cannot guarantee the adequacy, accuracy, timeliness or completeness of or be held responsible or liable for errors of fact regarding such data and information obtained from third parties, and this data may change with market conditions.
 



End of ad hoc announcement
Language: English
Company: HBM Healthcare Investments AG
Bundesplatz 1
6300 Zug
Switzerland
Phone: +41438887171
Fax: +41438887172
E-mail: info@hbmhealthcare.com
Internet: https://www.hbmhealthcare.com
ISIN: CH0012627250
Valor: 1262725
Listed: SIX Swiss Exchange
EQS News ID: 1201131

 
End of Announcement EQS Group News Service

1201131  27-May-2021 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1201131&application_name=news&site_id=boersengefluester_html
Visual performance / price development - HBM Healthcare Investments AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.